Pharma Stability: Insights, Guidelines, and Expertise
Stability reports play a critical role in defining the shelf life and quality profile of pharmaceutical products. However, any Good Manufacturing Practice (GMP) violations observed in the generation, documentation, or handling of stability data can lead to severe regulatory consequences—including FDA 483s, warning letters, or product recalls. This tutorial-style article explores the best practices and…
Excursions and out-of-specification (OOS) results are inevitable in long-term pharmaceutical stability studies. Whether due to chamber malfunction, unexpected assay drift, or analytical errors, these events must be thoroughly documented in the stability report. Regulatory agencies such as the USFDA, CDSCO, and EMA require a standardized approach to documenting, investigating, and concluding on such deviations. This…
Read More “Documenting Excursions and OOS Events in Reports” »